Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
Results showed that the CIC and flu vaccines generated 'robust immune responses' across three flu strains (H1N1, H3N2 and B) and the SARS-CoV-2 strain in adults aged 65 and older. Per Novavax, these responses were similar to those seen with its own approved COVID-19 vaccine, Nuvaxovid, and Sanofi's SNY influenza vaccine, Fluzone HD.
Novavax emphasized that this study was not designed to demonstrate statistical significance but to provide preliminary immunogenicity data. It intends to use these findings to design another late-stage study, which could potentially support regulatory submissions, if successful.
NVAX is also exploring strategic collaborations to finance further development and potential commercialization of both candidates. This is part of the company's recent strategic shift focused on expanding its pipeline and exploring partnership opportunities for the same.
Shares of Novavax have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
The above announcement came just under a month after it received the long-awaited FDA approval for Nuvaxovid, albeit with a narrower label than initially expected. While the agency granted full approval to the vaccine for use in older adults aged 65 and above, it restricted the use in individuals aged 12-64 with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
This latest approval aligns with the FDA's recently issued guidance for COVID-19 vaccine boosters. As part of this guidance, COVID vaccine makers will be required to conduct randomized, placebo-controlled clinical studies demonstrating the real-world benefit of yearly COVID vaccine boosters in individuals aged under 65 years.
Starting this year, Sanofi has acquired exclusive rights to market Nuvaxovid globally, except in certain territories where Novavax maintains existing partnership agreements. This arrangement is part of a multi-billion-dollar deal signed last year, wherein Sanofi assumed commercial responsibility for the vaccine. The company is also eligible for ongoing tiered royalties on future sales of COVID-19 vaccines.
Apart from Novavax, Pfizer PFE and Moderna MRNA are also developing their respective COVID/flu combination vaccines using mRNA technology.
Despite the recent regulatory setback, Moderna remains ahead of its competitors with the development of its investigational COVID-19/flu vaccine candidate, mRNA-1083. Moderna had to voluntarily withdraw its FDA filing for mRNA-1083 to accommodate the agency's request for additional efficacy data on the flu component of the vaccine. Moderna intends to resubmit the filing later this year.
Pfizer suffered a major setback in this space last year when it reported data from a phase III study on its investigational mRNA-based COVID-19/flu combination vaccine. The study missed one of its two primary immunogenicity objectives. Pfizer is currently evaluating adjustments to its combination vaccine program to improve immune responses against influenza B and plans to discuss the next steps with health authorities. Pfizer is developing this vaccine in collaboration with BioNTech.
Novavax's deal with Sanofi also allows the latter to combine its own influenza vaccines with Nuvaxovid. Sanofi is currently testing multiple COVID-19/flu combination vaccine candidates under this arrangement. Last year, the FDA granted fast-track designation to two of Sanofi's experimental combination vaccines, both being evaluated in separate phase I/II studies. While the first combination uses the Fluzone HD vaccine with Nuvaxovid, the second pairs Novavax's COVID-19 shot with Flubok.
Novavax, Inc. price | Novavax, Inc. Quote
Novavax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Moderna, Inc. (MRNA) : Free Stock Analysis Report
Novavax, Inc. (NVAX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Where Could Air Canada Stock Be in 5 Years?
Written by Andrew Button at The Motley Fool Canada Air Canada (TSX:AC) stock has been taking a beating in recent years. In 2020, in the early months of the COVID-19 pandemic, the stock fell all the way from $54 to $12, as the travel restrictions in that period caused the company's revenue to decline 80%. The company's stock later rallied when the first COVID vaccine was announced, but subsequently gave up the gains for reasons that are less clear. Today, Air Canada is in a much better place than it was in 2020. It's profitable. It has repaid much of its debt. Its revenue has recovered to its pre-COVID level and then some. Nevertheless, at around $19, AC stock is still nowhere near its pre-COVID stock price. What's going on here? There are a few lingering issues for Air Canada that have investors worrying about the stock, even though the underlying company is in a much better place than it was before the crash. The question is, why the apparent discrepancy? In this article, I will explore the reasons why Air Canada stock is still at a relatively low level and why I think it will be at a higher one in five years' time. One reason why some investors are concerned about Air Canada is because of the large amounts of capital expenditures (CAPEX) the company is undertaking in the next three years. CAPEX refers to spending on fixed assets like property, plant and equipment. In the case of an airline, it mainly refers to spending on new aircraft. Air Canada expects $3.4 billion in CAPEX in 2025, $4.3 billion in 2026, and $4.9 billion in 2027. After 2027, the CAPEX spend is expected to decline. The amounts of CAPEX above are fairly large. Notably, they exceed the company's past amounts of free cash flow, seeming to imply that Air Canada will be cash flow negative in the years ahead. Is this CAPEX such a big risk for Air Canada? In my opinion, no. Airplanes tend to be in service for decades, meaning that a lot of CAPEX now does not mean a lot of CAPEX in the future. Also, Air Canada's revenue has far surpassed levels seen in past years, so unprecedented CAPEX does not necessarily mean chronic cash burn. Overall, I don't think Air Canada's CAPEX is going to ruin the company. Another reason why people are concerned about Air Canada is because of Donald Trump's trade wars. Earlier this year, Trump slapped a 25% tariff on Canada, ostensibly to counter the flow of fentanyl into the United States. In response, many Canadians pledged to cancel vacations to the United States. Later, data collection firms reported that Canada-U.S. air travel did decline — one story claimed by as much as 70%. Air Canada said that it saw an impact but denied that its U.S. travel hours went down by 70%. Again, this strikes me as not that big of a risk. Canadians are most likely replacing U.S. travel with inter-provincial travel and overseas travel. Air Canada's most recent earnings release confirms this: revenue was stable year-over-year, and free cash flow was positive. On the whole, Air Canada looks like a bargain at 8.8 times earnings and 1.6 times operating cash flow. I think it will be worth more in five years' time than it is today. The post Where Could Air Canada Stock Be in 5 Years? appeared first on The Motley Fool Canada. More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Andrew Button has positions in Air Canada. The Motley Fool recommends Air Canada. The Motley Fool has a disclosure policy. 2025
Yahoo
an hour ago
- Yahoo
RFK Jr. Used 'Disinformation' to Defend Change to Vaccine Schedule, Expert Says: Reports
The Department of Health and Human Services sent Congress a document that cited disputed studies and misrepresented other findings, according to NPR and KFF Health News The document was written in support of Secretary Robert F. Kennedy Jr.'s decision to change federal COVID vaccine recommendations for healthy kids and pregnant women 'This is RFK Jr.'s playbook,' said Sean O'Leary, chair of the Committee on Infectious Diseases for the American Academy of PediatricsThe Department of Health and Human Services sent Congress a document to support Secretary Robert F. Kennedy Jr.'s decision to change federal vaccine recommendations that cited unpublished or disputed studies and misrepresented other findings, according to NPR and KFF Health News. In late May, Kennedy, who has a history of vaccine skepticism, announced on X that the Centers for Disease Control and Prevention (CDC) removed the COVID vaccine from the recommended immunization schedule for healthy children and pregnant women, while touting President Trump's Make America Healthy Again agenda. "It is so far out of left field that I find it insulting to our members of Congress that they would actually give them something like this. Congress members are relying on these agencies to provide them with valid information, and it's just not there," Dr. Mark Turrentine, a professor of obstetrics and gynecology at Baylor College of Medicine, told KFF Health News, the outlet that obtained the FAQ document. The outlet also reported that the document suggests a link between heart conditions like myocarditis or pericarditis and the COVID vaccine, but updated research suggests that connection has decreased with newer vaccine procedures. The document also left out multiple other peer-reviewed studies that show the risk of myocarditis and pericarditis is greater after getting sick with COVID for both vaccinated and non-vaccinated people than the risk of the same complications after vaccination alone, per KFF Health News. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "There is no distortion of the studies in this document. The underlying data speaks for itself, and it raises legitimate safety concerns. HHS will not ignore that evidence or downplay it. We will follow the data and the science," a HHS spokesperson told KFF Health News. 'This is RFK Jr.'s playbook,' Sean O'Leary, chair of the Committee on Infectious Diseases for the American Academy of Pediatrics, told KFF Health News. 'Either cherry-pick from good science or take junk science to support his premise — this has been his playbook for 20 years.' Read the original article on People
Hamilton Spectator
an hour ago
- Hamilton Spectator
From Dunnville to Niagara: Innovation, personalized care key to Hauser's Pharmacy longevity
While it's not quite accurate to say Phil Hauser comes from a long line of pharmacists — unless you call second generation a long line — the profession is in his blood. 'I took my first steps in the back room of the pharmacy,' he said. That would be Hauser's Pharmacy. The Dunnville business was opened by his father Jim, who with his mother Bonnie took over a long-running pharmacy in 1980. Over the next 45 years, it has remained a fixture in that town. It gradually spread across southern Ontario — its first offshoot was in St. Catharines in 2014 when Hauser's opened in the new hospital. Last year, Hauser's opened its second location in the region, in the former CIBC building on Queen Street in Niagara Falls, a site it shares with a physician clinic. All the while, the pharmacy has maintained its independence and commitment to personalized care. 'We recognize every patient wants something different from their health-care provider,' said Hauser, who took over the family business in 2007 following his graduation from pharmacy school. 'Some people simply want their prescription filled fast and effectively, and we do that. Some people want more. Some people have a lot of questions about their conditions, some people want to question a lot of the information that they find online, and some people need that personal connection before discussing things that are otherwise very personal.' Hauser's Pharmacy current owner Phil Hauser in front of the prescription counter at the Dunnville store in 2021. At the time, Hauser's was preparing to administer COVID-19 vaccines. About the same time he took over the business, Hauser was elected to Ontario Pharmacists Association, for which he served six years. Among other things during that time, he advocated for an increased role of pharmacists in patient health care. Hauser's was one of 32 pharmacies involved in a pilot program in Ontario offering flu shots — something that has since been rolled out across the province. But the advocacy and innovation has been a constant thread in the family business, Hauser said. In the early 1980s, his mom called on the Health Ministry to have tobacco products removed from pharmacy shelves. 'Even though it was a significant source of income for pharmacies, it flew in the face of being a health-care provider, and providing something that we knew was poisonous or a detriment to people's health in the same breath,' Hauser said. Bonnie and Jim Hauser at a computer terminal in their Dunnville pharmacy. In the early 1980s, Hauser's Pharmacy was one of the first in Ontario to incorporate computerized patient prescription records. Also in the 1980s, Hauser's was also one of the first pharmacies to incorporate computer records to track patient prescriptions . 'It's something we take for granted today, but back then you were flipping through people's prescriptions and just making sure the refills were still valid,' he said. 'There wasn't the same level of continuous care that we're used to.' Hauser's launching a mobility and home health care division in 2014, Supper Services, its in-home private care division in 2021 and a remote dispensary operation for an underserved community in the Muskoka region in 2022. Hauser said this history of innovation and ability to provide a continuum of care for patients is what made the business an attractive choice for pharmacy partner with the now-named Marotta Family Hospital in St. Catharines. 'They recognized that our mission, our philosophy of bringing better patient care, was a key tenant that the NHS wanted to do, which was to guide the continuity of care for patients that were leaving outpatient clinics or were leaving the hospital altogether, and then making sure they had the proper transition into community care,' he said. This year, the pharmacy is marking its 45th anniversary at all nine of its stores with monthly giveaways, sales o throughout the year, children's colouring contests and rolling discounts. See its website, , to sign up to receive information or follow Hauser's on its social media channels. Hauser said their ability to remain independent lies in them striving to provide continual value for their patients. 'We want to provide the best level of health care,' he said. 'And I think that's not always something that's evident until you experience it. And when you experience it … my hope is when you come into a Hauser's Pharmacy and you notice a difference in the quality of care that that means something to you.'
